Sunflower Pharmaceutical Group Co.,Ltd (SHE:002737)
China · Delayed Price · Currency is CNY 14.02
+0.04 (0.29%)
Feb 3, 2026, 3:04 PM CST
SHE:002737 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,079 | 3,362 | 5,686 | 5,083 | 4,454 | 3,457 |
Other Revenue | 14.94 | 14.94 | 14.62 | 11.03 | 6.55 | 4.83 |
| 2,094 | 3,377 | 5,700 | 5,095 | 4,461 | 3,462 | |
Revenue Growth (YoY) | -52.75% | -40.76% | 11.89% | 14.20% | 28.86% | -20.81% |
Cost of Revenue | 1,529 | 1,896 | 2,493 | 2,157 | 1,822 | 1,450 |
Gross Profit | 565.27 | 1,481 | 3,208 | 2,938 | 2,639 | 2,012 |
Selling, General & Admin | 620.59 | 854.08 | 1,839 | 1,751 | 1,643 | 1,192 |
Research & Development | 110.8 | 124.13 | 128.65 | 94.61 | 132.07 | 113.56 |
Other Operating Expenses | 125.76 | 42.25 | 60.82 | 69.4 | 65.56 | 51.03 |
Operating Expenses | 846.67 | 1,028 | 2,024 | 1,916 | 1,867 | 1,350 |
Operating Income | -281.4 | 452.83 | 1,184 | 1,022 | 771.33 | 661.92 |
Interest Expense | -3.16 | -3.56 | -5.97 | -9.73 | -10.19 | -7.39 |
Interest & Investment Income | 40.54 | 52.21 | 85.35 | 30.56 | 44.09 | 29.02 |
Currency Exchange Gain (Loss) | 0.05 | 0.05 | -0.09 | 0.11 | - | - |
Other Non Operating Income (Expenses) | -1.73 | 1.08 | -2.42 | -4.56 | -0.24 | -0.8 |
EBT Excluding Unusual Items | -245.71 | 502.61 | 1,260 | 1,039 | 805 | 682.74 |
Impairment of Goodwill | -4.8 | -4.8 | - | -15.83 | -27.22 | -36.73 |
Gain (Loss) on Sale of Investments | -4.33 | -12.99 | -16.39 | -19.31 | 2.67 | - |
Gain (Loss) on Sale of Assets | 0.6 | -0.24 | 3.23 | 7.43 | 47.77 | -5.41 |
Asset Writedown | -24.18 | -20.99 | -0.48 | -10.6 | -2.46 | -1.97 |
Other Unusual Items | 162.3 | 170.89 | 108.02 | 80.63 | 68.76 | 128.2 |
Pretax Income | -116.11 | 634.49 | 1,355 | 1,081 | 894.51 | 766.83 |
Income Tax Expense | 32.58 | 131.76 | 189.83 | 171.37 | 132.16 | 146.89 |
Earnings From Continuing Operations | -148.7 | 502.73 | 1,165 | 909.73 | 762.35 | 619.94 |
Minority Interest in Earnings | 20.37 | -10.69 | -45.8 | -42.51 | -57.61 | -35.48 |
Net Income | -128.33 | 492.05 | 1,119 | 867.22 | 704.74 | 584.45 |
Net Income to Common | -128.33 | 492.05 | 1,119 | 867.22 | 704.74 | 584.45 |
Net Income Growth | - | -56.03% | 29.05% | 23.06% | 20.58% | 3.37% |
Shares Outstanding (Basic) | 565 | 586 | 583 | 586 | 582 | 584 |
Shares Outstanding (Diluted) | 565 | 586 | 583 | 586 | 582 | 584 |
Shares Change (YoY) | -4.05% | 0.49% | -0.53% | 0.61% | -0.35% | 0.27% |
EPS (Basic) | -0.23 | 0.84 | 1.92 | 1.48 | 1.21 | 1.00 |
EPS (Diluted) | -0.23 | 0.84 | 1.92 | 1.48 | 1.21 | 1.00 |
EPS Growth | - | -56.25% | 29.73% | 22.31% | 21.00% | 3.09% |
Free Cash Flow | 229.28 | -400.27 | 740.52 | 1,822 | 746.92 | 957.14 |
Free Cash Flow Per Share | 0.41 | -0.68 | 1.27 | 3.11 | 1.28 | 1.64 |
Dividend Per Share | 0.500 | 0.500 | 1.500 | 1.000 | 0.700 | 0.350 |
Dividend Growth | -66.67% | -66.67% | 50.00% | 42.86% | 100.00% | -65.00% |
Gross Margin | 26.99% | 43.85% | 56.27% | 57.67% | 59.15% | 58.12% |
Operating Margin | -13.44% | 13.41% | 20.76% | 20.07% | 17.29% | 19.12% |
Profit Margin | -6.13% | 14.57% | 19.63% | 17.02% | 15.80% | 16.88% |
Free Cash Flow Margin | 10.95% | -11.85% | 12.99% | 35.77% | 16.74% | 27.65% |
EBITDA | -110.07 | 625.66 | 1,358 | 1,285 | 935.8 | 811.07 |
EBITDA Margin | -5.26% | 18.53% | 23.83% | 25.22% | 20.98% | 23.43% |
D&A For EBITDA | 171.33 | 172.83 | 174.82 | 262.65 | 164.47 | 149.15 |
EBIT | -281.4 | 452.83 | 1,184 | 1,022 | 771.33 | 661.92 |
EBIT Margin | -13.44% | 13.41% | 20.76% | 20.07% | 17.29% | 19.12% |
Effective Tax Rate | - | 20.77% | 14.01% | 15.85% | 14.77% | 19.16% |
Revenue as Reported | 2,094 | 3,377 | 5,700 | 5,095 | 4,461 | 3,462 |
Advertising Expenses | - | 217.86 | 1,078 | 1,068 | 115.37 | 127.86 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.